Elanco Animal Health Inc

Elanco Animal Health Inc (ELAN) Stock Analysis

$23.540

+1.033 (+4.39%)At close

Loading chart…
High
23.790
Open
22.830
VWAP
23.38
Volume
6.65M
Mkt Cap
7.05B
Low
22.800
Amount
155.51M
EV/EBITDA, TTM
12.65

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

AI analysis of Elanco Animal Health Inc (ELAN)

Buy

Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.

Analyst Ratings (11)

+8.33% upside
Hold
5 Buy
6 Hold
0 Sell
Current: 23.54
Low
22.00
Average
25.50
High
30.00

KeyBanc

2026-08-06

Price Target

$30

Overweight

Citi

2026-08-06

Price Target

$34

Buy

Morgan Stanley

2026-07-22

Price Target

$26

Equal Weight

TD Cowen

2026-06-18

Price Target

$32

Buy

Morgan Stanley

2026-05-15

Price Target

$23

Equal Weight

Valuation Metrics

The current forward P/E ratio for Elanco Animal Health Inc (ELAN) is 17.36, compared to its 5-year average forward P/E of 17.72.

Forward P/E

Fair
5Y Average P/E
17.72
Current P/E
17.36
Overvalued
22.08
Undervalued
13.37

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.65
Current EV/EBITDA
12.65
Overvalued
16.49
Undervalued
10.80

Forward P/S

Fair
5Y Average P/S
1.80
Current P/S
2.09
Overvalued
2.37
Undervalued
1.24

Alphio AI Price Scenarios for ELAN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ELAN

$13.97

Scenario price

B

Base

Base · 50%ELAN

$13.55

Scenario price

B

Bear

Bear · 25%ELAN

$10.58

Scenario price

Whales holding ELAN

D

Douglas Lane & Associates, LLC

+ HoldingELAN

+5.47%

3M Return

P

PRIMECAP Management Company

+ HoldingELAN

+2.18%

3M Return

B

Bowen, Hanes & Company, Inc.

+ HoldingELAN

-0.83%

3M Return

Events Timeline

2026-08-26 (ET)

09:00:00

Elanco Animal Health Completes 25,000-SF Manufacturing Expansion

2026-08-07 (ET)

15:00:00

Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations

2026-08-05 (ET)

07:00:00

Elanco Reports Q2 Revenue of $1.37B, Beating Consensus

07:00:00

Elanco Animal Health Raises FY26 Revenue Outlook to $5.09B-$5.14B

2026-06-18 (ET)

07:30:00

Elanco Animal Health Establishes Elanco Ventures Investment Platform with $25M Commitment

News

ELAN FAQ — answered by Alphio AI

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading